We are pleased to announce our collaboration with ENEAPHARM through the SKYEHUB platform.
This partnership aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. With this collaboration, Skyepharma strengthens its positioning as a BIO CDMO, reinforcing its ambition to become a key player in the development of the biotechnology sector; both in the Auvergne-Rhône-Alpes region, and more broadly in France and across Europe.
The Skyehub offers tailored support for the industrialization of biomedicines, leveraging deep expertise in drug development, industrial scale-up, and pharmaceutical release.
Karim IOUALAEN, Équipe SKYEHUB